EULAR: Routine, proactive therapeutic drug monitoring unnecessary in RMDs
Routine, proactive therapeutic drug monitoring for patients receiving biopharmaceuticals for rheumatic and musculoskeletal diseases is not recommended, according to new points-to-consider published by EULAR.“Understanding whether…